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In this pharmacogenetic study in adults with
ADHD (n¼42), a stratified analysis was performed
of the association between response to methyl-
phenidate (MPH), assessed under double-blind
conditions, and polymorphisms in the genes
encoding the dopamine transporter, SLC6A3
(DAT1), the norepinephrine transporter, SLC6A2
(NET), and the dopamine receptor D4, DRD4. The
VNTR polymorphism in the 30 untranslated region
of SLC6A3 was significantly associated with an
increased likelihood of a response to MPH treat-
ment (OR 3.8; 95% CI 1.0–15.2, and OR 5.4; 95% CI
1.4–21.9, depending on the definition of response)
in carriers of a single 10-repeat allele compared to
patients with the 10/10 genotype. The polymorph-
isms in DRD4 and the SLC6A2 were not associated
with treatment response. This study supports a
role of the SLC6A3 genotype in determining the
response to MPH in the treatment of adults with
ADHD.  2007 Wiley-Liss, Inc.
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INTRODUCTION
Attention deficit/hyperactivity disorder, or ADHD, is a
neuropsychiatric disorder that affects between 3% and 6% of
children worldwide [Faraone et al., 2003]. Family studies
[Cantwell, 1972; Biederman et al., 1992; Faraone et al., 2005]
as well as twin studies [e.g., Levy et al., 1997; Rietveld et al.,
2004] and adoption studies [Moore and Fombonne, 1999;
Sprich et al., 2000] point to a strong genetic component in
ADHD, with heritability estimates of 60% to 90% [Levy et al.,
1997; Faraone et al., 2005]. Symptoms of the disorder persist
into adulthood in more than 60% of cases and prevalence rates
up to 5% in adults have been reported [Biederman et al., 2000;
Barkley et al., 2002; Kooij et al., 2005; Faraone et al., 2006;
Kessler et al., 2006]. Treatment with stimulants such as
methylphenidate (MPH) and D-amphetamine is effective in
about 70% of children and in 25–78% of adults, depending on
patient samples, doses, and outcome measures used [Spencer
et al., 1996; Faraone et al., 2004].
Several studies have implicated genetics not only in ADHD
susceptibility, but also in the response to medication. A pilot
study of our own group in 28 sib pairs with MPH-treated ADHD
suggested familial clustering of MPH response based on a
significant correlation of MPH response between siblings [van
der Meulen et al., 2005]. A number of genes thought to be
associated with an increased ADHD risk have been tested for
their association with the response to MPH in childhood ADHD
[for reviews also see References McGough, 2005; Polanczyk
et al., 2005; Khan and Faraone, 2006]. Most studies have
evaluated the SLC6A3 gene, which encodes a direct target of
MPH action, the dopamine transporter DAT1. Studies have
concentrated on a variable number of tandem repeat poly-
morphism (VNTR) in the 30 untranslated region of this gene,
which appears to be associated with ADHD [Cook et al., 1995;
Waldman et al., 1998; Daly et al., 1999; Curran et al., 2001],
although recent meta-analyses results are contradictory and
suggest heterogeneity in the findings [Li et al., 2006; Yang
et al., 2007]. The studies regarding the involvement of this
variant in MPH treatment outcome have yielded rather
inconsistent results. Winsberg and Comings [1999] were
the first to report a poorer response to MPH in patients
homozygous for the 10 repeat allele (the ADHD ‘‘risk allele’’) in
a prospective study of 30 ADHD children. Roman et al. [2002]
replicated these findings in their prospective study of 50
children with ADHD, as did Cheon et al. [2005] in their study of
11 children. Furthermore, a recent study in 16 children with
ADHD investigating the effect of single-dose treatment (with
MPH or atomoxetine) on short interval cortical inhibition
(SICI) also found significant effects of SLC6A3 genotype, with
increasing SICI in heterozygotes for the 10-repeat allele, but
decreasing SICI in homozygotes [Gilbert et al., 2006]. SICI is
reduced in ADHD patients compared to controls and is a
possible neurophysiological marker of behavioral symptoms
in ADHD [Moll et al., 2000]. Kirley et al. [2003] on the other
hand, found that an increased response to MPH was associated
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with transmission of the 10-repeat allele in their retrospective,
family-controlled association study that included 119 children
with ADHD. Evidence that it is the 9-repeat allele rather than
the 10-repeat allele that is associated with impaired response
to MPH was provided by Stein et al. [2002]: the researchers
found that homozygotes for the 9-repeat allele had an impaired
response to MPH in a prospective study of 47 children [Stein
et al., 2002]. As the authors stated, this association had also
been found in an extended analysis of the sample reported
earlier by Kirley et al. [referenced in Stein et al., 2005].
Interestingly, Lott et al. [2005] also observed subjective non-
response in individuals with the 9/9 genotype (n¼ 8) in a recent
study of the effects of the 30 VNTR in SLC6A3 on the effects of D-
amphetamine in 96 adult healthy volunteers. In contrast to
these reports, McGough et al. [2006] found no effect of the 10-
repeat allele on MPH-induced symptom reduction in ADHD in
their prospective study in 81 preschool children with ADHD as
did a study by our own group in 82 children from 54 families
[van der Meulen et al., 2005]. No effect of the polymorphism in
SLC6A3 (in addition to polymorphisms in DRD4, HTR1B,
HTR2A, and 5-HTT) on treatment response or adverse effects
was reported by Zeni et al. [2007] after 1 month of treatment
with MPH in 111 children with ADHD, either. A recent study of
106 adults with ADHD also failed to support a role of the 30 UTR
polymorphism in response to MPH (both immediate release
MPH and longacting OROS MPH) [Mick et al., 2006. Subjects
homozygous for the 10-repeat allele were not distinguishable
from heterozygous 9/10 or homozygous 9-repeat allele carriers
in their level of symptom reduction or in adverse effects.
In conclusion, currently there is some evidence for both of the
frequent SLC6A3 alleles, the 10- and the 9-repeat allele, being
associated with reduced response to MPH, though a number of
studies find no effect at all.
A second gene studied for its effect on MPH treatment
outcome is DRD4, a gene consistently found to be associated
with ADHD, which encodes the dopamine receptor D4 [for
meta-analysis see Faraone et al., 2005; Li et al., 2006].
Although this protein is not a direct target of MPH, it is an
important determinant of dopamine action. In the study by
Winsberg and Comings [1999] mentioned above, no effect of a
48-base pair repeat polymorphism in the third exon of DRD4
(nor of a variant in the DRD2 gene] on the response to MPH was
observed. Seeger et al. [2001], in a prospective study involving
47 children with hyperkinetic disorder (a syndrome classified
according to ICD-10 that includes a subgroup of ADHD
patients classified by DSM-IV criteria), found the 7R allele of
this polymorphism (which is a risk factor for ADHD and
associated with a blunted response of the receptor to ligand
binding [Asghari et al., 1994, 1995] to be associated with a
reduced response to MPH treatment. This was only observed,
however, in interaction with a functional polymorphism of
SLC6A4 (5-HTT), the gene encoding the serotonin transporter.
A study by Hamarman et al. [2004] found the 7R allele to
be associated with a higher dose of MPH needed to achieve
treatment response in a sample of 45 children with ADHD.
Our own study in 82 children found only a trend towards
association of response to MPH in individuals with one or two
7R alleles [van der Meulen et al., 2005], the study by Zeni et al.
[2007] found no effect. A second polymorphism in the DRD4
gene is a 120-bp tandem duplication polymorphism in the 50
flanking region [Seaman et al., 1999]. This polymorphism
changes the regulation of the receptor, the longer allele has
lower transcriptional activity than the shorter allele [D’Souza
et al., 2004]. Minor (non-significant) effects of this poly-
morphism on response to MPH were reported by McGough
et al. [2006] in their prospective study of 81 preschoolers with
ADHD.
The norepinephrine transporter might be another target of
MPH, and one article reported an association between a single
nucleotide polymorphism (SNP) in the SLC6A2 gene encoding
this transporter and a reduced treatment response to MPH in a
sample of 45 children [Yang et al., 2004]. The recent study by
McGough et al. [2006], mentioned above, also showed some
evidence for the involvement of a genetic variant in the
SNAP25 gene (encoding the synaptosomal-associated protein
25 involved in synaptic vesicle transport) in response to MPH
treatment. In addition, a study by Polanczyk et al. [2007] found
association of the ADRA2A gene encoding the alpha 2A
adrenoreceptor with reduction of inattentive symptoms during
3 months of MPH treatment in 106 children and adolescents
with ADHD.
For genes that have been studied several times, results often
seem inconsistent. The reasons for that are not quite clear, but
surely include the mostly small sample sizes used, differences
in the design of the studies (e.g., retrospective vs. prospective),
MPH dose used and differences in the diagnosis of ADHD and
the definition of response to treatment.
To date, almost all pharmacogenetic studies of MPH have
focused on treatment in children, exclusively; however, MPH is
equally important for the treatment of adults with persistent
ADHD of childhood onset. Predictive pharmacogenetic testing
in adults may lead to better treatment choices and dosing
regimens. We therefore investigated the role of genes with a
possible effect on treatment response in children, namely
DRD4, SLC6A3, and SLC6A2, in the response of adults with




DNA was obtained from 42 of 45 adults with ADHD,
regardless of subtype, who were participating in a double-
blind, randomized, placebo-controlled crossover study of
immediate release MPH, the results of which have been
reported elsewhere [Kooij et al., 2004]. Only subjects with a
CGI-severity (CGI-S) equal or greater than 4, and who were
impaired in two or more settings were included. Raters were
two experienced psychiatrists in adult ADHD, who discussed
every patient included in the study.
Subjects with comorbid psychiatric disorders were included
unless these disorders had to be treated first or if treatment
with MPH was contraindicated. Subjects were prospectively
excluded if they had clinically relevant medical conditions,
abnormal baseline laboratory values, a history of tic disorders,
IQ< 75, organic brain disorders, clinically unstable psychia-
tric conditions (i.e., suicidal behaviors, psychosis, mania,
physical aggression, currently ongoing substance abuse),
current use of psychotropics, or prior use of MPH or amphet-
amines; pregnant or nursing women were also excluded. The
study was approved by the local Medical Ethics Committee of
the Reinier de Graaf Hospital in Delft. All subjects completed
a written informed consent form before inclusion in the
study.
Assessments
Prior to inclusion, patients underwent an extensive clinical
assessment for ADHD and comorbidity [Kooij et al., 2004]. The
diagnosis of childhood-onset and current ADHD was deter-
mined by a psychiatrist’s clinical evaluation supplemented by
the Dutch version of the DSM-IV ADHD-rating scale for
current symptoms during the last 6 months [DuPaul et al.,
1998; Kooij et al., 2005].
For a full diagnosis of adult ADHD, subjects had to (1) meet
6 of 9 DSM-IV criteria of inattention and/or hyperactivity/
impulsivity for a diagnosis of ADHD in childhood and at least 5
202 Kooij et al.
of 9 criteria of one or both domains in adulthood; (2) describe a
chronic persisting course of ADHD symptoms from childhood
to adulthood; and (3) experience a moderate-to-severe level of
impairment attributed to the ADHD symptoms. A cut-off point
of 5 of 9 criteria was set for diagnosis of adult ADHD based on
the literature and epidemiological data obtained with the same
DSM-IV ADHD-Rating Scale [Murphy and Barkley, 1996;
Biederman et al., 2000; Kooij et al., 2005; McGough et al.,
2005].
Childhood onset of symptoms and impairment (before
12 years of age) was retrospectively assessed by interviewing
the patients and their parents or siblings. In addition, partners
were interviewed about current symptoms and impairment.
Collateral information was available from family members of
39 patients (34 parents and 5 siblings) and of all partners (27).
All family members confirmed the diagnosis to a certain extent.
The extent varied between ‘‘very likely’’ (24 family members
and 24 partners), ‘‘likely’’ (7 family members and 3 partners),
and ‘‘possible’’ (8 family members). In addition, in 38 school
reports available from 41 patients, comment on behavior
supporting the diagnosis in childhood was found.
Study Design and Outcome
A randomized, placebo-controlled, double-blind cross-over
trial comparing immediate-release MPH with placebo was
performed. There were two to three-week treatment periods
with one week of washout in between. The order of treatment
(methylphenidate-placebo or placebo-methylphenidate) was
randomized. Medication was prescribed standard every 3–
4 hr, resulting in four or five times a day dosing, between 8.00
am and 8.00 pm. Dosing was adjusted to five times a day when
rebound occurred. Subjects used a device (Memos) containing
compartments for the tablets and a timer in order to dose
on time. Study treatment was prescribed at 0.5 mg/kg/day
by week 1, followed by 0.75 mg/kg/day by week 2, and up to
1.0 mg/kg/day by week 3. Only the highest dose was considered
for measurement of response.
The Dutch self-report-version of the DSM-IV ADHD-rating
scale [DuPaul et al., 1998] which is sensitive to drug effects in
pediatric [Barkley 2006] and adult [Spencer et al., 1995]
samples, was used weekly to assess symptoms of ADHD. For
the analyses the scores were first averaged over days of
the week and subsequently over all items. Severity of ADHD
was assessed weekly with the global severity subscale of the
Clinical Global Impression Scale for ADHD (CGI-ADHD; 1
indicates not ill; 7 indicates extremely ill), which is also
sensitive to drug effects [NIMH, 1985]. The primary study
outcome was clinical response, defined rather strictly a priori
as a decrease of at least 2 points on the investigator-based CGI-
ADHD severity scale over the total treatment period (3 weeks),
as well as a 30% or greater symptom reduction as measured
with the self-reported DSM-IV ADHD-rating scale. The
two secondary measures of clinical response were a decrease
of at least 2 points on the investigator-based CGI-ADHD
severity scale, and a 30% or greater symptom reduction as
measured with the self-reported DSM-IV ADHD-rating scale,
taken separately.
DNA Isolation and Genotyping
EDTA blood was collected from 42 adult patients. High
molecular DNA was isolated by a routine procedure [Miller
et al., 1988].
Genotyping was performed for two polymorphisms in the
gene encoding the dopamine receptor 4, DRD4, the 120-bp
tandem insertion/deletion (ins/del) polymorphism upstream
of exon 1 [Seaman et al., 1999], and the polymorphism in exon
3 consisting of a variable number of direct imperfect 48-bp
repeats [Van Tol et al., 1992]. The former polymorphism was
genotyped using a PCR-based method essentially as described
by Seaman et al. [1999]. PCR was on 62.5 ng genomic DNA
using 0.4 mM of forward primer (50-GTTGTCTGTCTTTTC-
TCATTGTTTCCATTG-30) and 0.4 mM reverse primer (50-
GAAGGAGCAGGCACCGTGAGC-30), 0.25 mM dNTPs, 0.5 U
Taq DNA polymerase (Invitrogen, Breda, The Netherlands) in
a PCR buffer containing 10 mM Tris-HCl pH 8.0, 50 mM KCl,
0.1% Triton X-100 (v/v), 0.015% gelatin (w/v), 5% DMSO (v/v)
and 1.5 mM MgCl2. PCR products were analyzed on a 1.5%
agarose gel. The amplification yielded distinct bands at 429 bp
(short ‘‘S’’ allele) and 549 bp (long ‘‘L’’ allele). The 48-bp direct
repeat polymorphism in DRD4 was genotyped as described by
Lichter et al. [1993]. With 31.25 ng of genomic DNA as
template, PCR was performed with 0.4 mM forward primer
(50-GCGACTACGTGGTCTACTCG-30) and reverse primer
(50-AGGACCCTCATGGCCTTG-30), 0.25 mM dNTPs, 0.11 mM
7-deaza GTP (Amersham Biosciences, Roosendaal, The
Netherlands), 1 U AmpliTaq Gold DNA polymerase (Applied
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands), 60 mM
Tris-HCl (pH 8.5), 15 mM (NH4)2SO4, 10% DMSO (v/v) and
2 mM MgCl2. Analysis of the PCR products on a 1.5% agarose
gel showed bands at 378 bp (2 repeats), 426 bp (3 repeats),
474 bp (4 repeats), 522 bp (5 repeats), 570 bp (6 repeats), 618 bp
(7 repeats), or 666 bp (8 repeats).
The 40-bp VNTR in the 30 untranslated region of the SLC6A3
gene encoding the dopamine transporter was genotyped as
described by Michelhaugh et al. [2001] and Vandenbergh et al.
[1992]. Genomic DNA (62.5 ng) was amplified with 0.4 mM of
forward primer (50-TGTGGTGTAGGGACGGCCTGAGAG-30)
and reverse primer (50-CCTTGAGCCGTGACCTCCAGGAA-
30) with 0.25 mM dNTPs, 0.5 U Taq DNA polymerase
(Invitrogen) in a PCR buffer containing 60 mM Tris-HCl
(pH 8.5), 15 mM (NH4)2SO4, 10% DMSO (v/v) and 3.5 mM
MgCl2. Analysis of PCR products was on a 2% agarose gel,
producing bands at 443 bp (9 repeats), 483 bp (10 repeats), or
523 bp (11 repeats).
The 4-bp insertion/deletion polymorphism [NETpPR; Urwin
et al., 2002] in the promoter region of the SLC6A2 gene coding
for the norepinephrine transporter was analyzed by fragment
analysis, using an ABI3100 Genetic Analyser (Applied Bio-
systems). For the amplification of a PCR fragment containing
the variation from 62.5 ng of genomic DNA, a 3-primer system
was used with 0.04mM forward primer carrying a universal tail
(50-GGGACACCGCTGATCGTTAGCAGTGTAATATATGCC-
TATTGTCC-30, the universal tail is underlined), 0.4 mM reverse
primer (50- GGAGGAGAGGTTTGCCTAC-30), and 0.36 mM of
either a 6FAM-, VIC-, or NED-labeled universal primer. In this
assay, one of three possible universal primers of different length
and labeled with a different fluorescent dye was used
for each sample (50-6FAM-GGGACACCGCTGATCGTTA-30,
50-VIC-ACGGGACACCGCTGATCGTTA-30, 50-NED-GACGGG-
ACACCGCTGATCGTTA-30; stuffer-sequence is underlined).
The PCR also contained 0.25 mM dNTP and 1 U Taq DNA
polymerase (Invitrogen) in 10 mM Tris-HCl, pH 8.0, 50 mM
KCl, 1.5 mM MgCl2, 1% Triton X-100 (v/v), and 0.15% gelatin
(w/v). PCR products containing three different fluorescent
labels were pooled for further analysis. The pooling ratio for the
fluorescent PCR products containing 6FAM, VIC, and NED
was 1:1:1. Genotyping was performed using 1.5 ml of the pooled
PCR product together with 9.7 ml formamide and 0.3 ml
GeneScan-500 Liz Size StandardTM (Applied Biosystems) on
an ABI3100 Genetic Analyzer according to the manufacturer’s
protocol (Applied Biosystems). Analysis of the PCR products
with Genemapper software (Applied Biosystems) showed
fragments at 476 bp and 480 bp (using universal 6FAM-labeled
primer); 478 bp and 482 bp (using universal VIC-labeled
primer), and at 479 bp and 483 bp (using universal NED-
labeled primer).
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The cycling conditions for most of the PCR assays were
similar, starting with 5 min at 928C, followed by 35 cycles of
1 min at 928C, 1 min at the optimized annealing temperature
(588C for the DRD4 120-bp tandem duplication, the 40-bp
VNTR in SLC6A3, and the NETpPR polymorphism in
SLC6A2), and 1 min 728C (2 min in case of NETpPR), then
followed by an extra 5 min 728C. The cycling conditions for the
48-bp repeat polymorphism in DRD4 started with 10 min at
928C, followed by 40 cycles of 45 sec at 958C, 45 sec at 548C, and
75 sec at 728C, with a final extension for 10 min at 728C. The
amplifications were performed in a PTC-200 Multicycler (MJ-
Research via Biozym, Landgraaf, The Netherlands).
Statistics
Responder and non-responder characteristics were com-
pared using Pearson’s Chi-square test, Fisher’s exact test or
the Mann-Whitney U-test, where appropriate.
The genotype frequencies were tested for Hardy–Weinberg
equilibrium by Chi-square analysis. In the main analysis, data
were stratified by treatment (placebo or MPH). Only the
results for MPH treatment are presented. Differences in
genotype frequencies between responders and non-responders
were analyzed using Chi-square tests. When cell frequencies
dropped below five, Fisher’s exact test was applied. Odds ratios
and 95% confidence intervals were generated through logistic
regression analysis. Based on the results of the stratified
analysis, a random effects logistic regression model was used to
formally test for statistical interaction between the genetic
variants of the polymorphisms and treatment response while
taking the crossover design into account. Analysis took place
on an intention-to-treat principle.
All P-values were two-tailed and P-values below 0.05 were
considered significant. Since this was considered a purely
explorative study, no correction for multiple testing was
applied. Analyses were performed in Stata 8.0 (StataCorp.
2003. Stata Statistical Software: Release 8.0 College Station,
TX: StataCorp LP).
RESULTS
All participants were of Caucasian ethnic origin. None had
been treated with stimulants before. Median IQ was 101.5
(range 76–142); the percentage of participants with
primary, secondary, and tertiary educational level was
54.8%, 33.3%, and 11.9%, respectively. Mean baseline scores
were 1.67 (SD 0.52) for the self-report DSM-IV ADHD-rating
scale and 5.57 (SD 0.91) for the investigator-reported CGI
severity score; after treatment, these scores were 1.26
(SD 0.71) and 4.41 (SD 1.64), respectively. Most partici-
pants (76.2%) were diagnosed with lifetime comorbid disorders
(median 2, range 1–9), the main ones being mood disorders
(52.4%), anxiety disorders (45.2%), substance use disorders
(SUD; 40.5%), eating disorders (7.1%), and personality
disorders (33.3%). Sixteen participants (38.1%) responded to
treatment (responders), as defined by a decrease of at least 2
points on the investigator-based CGI-ADHD severity scale
over the total treatment period (3 weeks), plus a 30% symptom
reduction or more as measured by the self-report DSM-IV
ADHD-rating scale. Twenty-six (61.9%) patients did not show
a clinical response to MPH and were labeled non-responders.
MPH response rates were 51% and 42% for the CGI-S and
ADHD-RS, respectively.
Mean MPH doses at endpoint were not different between
responders and non-responders (0.94 mg/kg vs. 0.93 mg/kg).
The characteristics of both groups are given in Table I. Non-
responders had significantly more lifetime comorbid disorders
(P¼ 0.009). The number of patients with lifetime SUD was
borderline significantly more frequent in the group of non-
responders (P¼ 0.05).
The frequency of genotypes detected in the total group is
listed in Table II. These were comparable to those found in
other studies of individuals of Caucasian ethnic origin
(ALFRED database: http://alfred.med.yale.edu/alfred/index.-
asp) [Bakker et al., 2005]. Testing for Hardy–Weinberg
equilibrium did not reveal a significant deviation from
expected values (DRD4 (120-bp ins/del): P¼ 0.758; DRD4 (48-
bp repeat): P¼ 0.155; SLC6A2: P¼ 0.758; SLC6A3: P¼ 0.255).
The results of the stratified analysis of response to MPH are
presented in Table II. No association was found between
treatment response and the DRD4 120-bp ins/del or the 48-bp
repeat in this gene. For the latter polymorphism, the analysis
was performed for association of carriership of the 7R (the
‘‘ADHD risk allele’’) and/or the 2R allele compared to a group of
all other genotypes only, due to the large number of observed
alleles. The 2R allele was included because it seems to be
derived directly from the 7R allele by recombination, it is also
associated with a blunted response of the receptor to ligand
binding, and is a risk factor for ADHD, at least in individuals
with an Asian ethnic background [Wang et al., 2004; Leung
et al., 2005].
The NETpPR polymorphism in SLC6A2 was also not
associated with the response to MPH.
TABLE I. Demographics of the Study Population
Variable Total N (%) Non-responders N (%) Responders N (%) Statisticsa P-value
42 (100) 26 (61.9) 16 (38.1)
Age, median (range) 42.5 (20.1–55.7) 43.0 (20.1–55.7) 42.0 (20.1–52.1) n.s.
Sex: Male N (%) 23 (54.8) 16 (61.5) 7 (43.8) n.s.
ADHD combined type (%) 40 (95.2) 26 (100) 14 (87.5) n.s.
Baseline ADHD-RS score, mean (SD) 1.67 (0.52) 1.64 (0.48) 1.71 (0.60) n.s.
Baseline CGI-S score, mean (SD) 5.57 (0.91) 5.65 (0.75) 5.44 (1.15) n.s.
Total IQ, mean (SD) 101.83 (18.24) 99.15 (18.94) 106.19 (16.69) n.s.
Any lifetime comorbid disorder, N (%) 32 (76.5) 18 (69.2) 14 (87.5) n.s.
Number of lifetime comorbid disorders,
median (range)
2 (1–9) 3 (1-8) 1 (1–9) P¼0.009
Type of lifetime comorbid disorders, N (%)
Mood disorders 22 (52.4) 14 (53.9) 8 (50.0) n.s.
Anxiety disorders 19 (45.2) 12 (46.2) 7 (43.8) n.s.
Substance use disorders 17 (40.5) 14 (53.8) 3 (18.8) P¼ 0.05
Eating disorders 3 (7.1) 1 (3.8) 2 (12.5) n.s.
ADHD-RS: DSM-IV ADHD rating scale; CGI-S: Clinical Global Impression, Severity scale.
aResponder and non-responder characteristics were compared using Pearson’s Chi-square test, Fisher’s exact test or the Mann–Whitney U-test, where
appropriate. n.s.¼non-significant.
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The VNTR in SLC6A3 was almost significantly associated
with treatment response when comparing the group of
heterozygotes for the allele with 10-repeat units and the
10/10 homozygotes (the 10-repeat allele is the ‘‘ADHD risk
allele’’). The single 9/9 homozygous patient was removed from
the analysis, since according to the publication of Lott et al.
[2005] this genotype might have significantly different effects
from the heterozygous genotypes containing the 10-repeat
allele and should therefore be considered separately. Whereas
52.2% of the participants heterozygous for the 10-repeat allele
showed a significant improvement in their condition with MPH
treatment (12 out of 23), only 22.2% of the 10/10 homozygous
individuals achieved a comparable response (4 out of 18) (OR
3.8; 95% CI 1.0–15.2). When we looked at the two measures of
response (CGI-ADHD severity scale and self-report DSM-IV
ADHD-rating scale) separately (Table III), we found a statisti-
cally significant increased odds ratio for MPH treatment
response (OR 5.4; 95% CI 1.4–21.9) in the heterozygous
10-repeat allele carriers in comparison with the 10/10
homozygotes for the self-report data, but not for the inves-
tigator-based CGI-ADHD severity scale score (OR 1.6; 95% CI
0.5–5.6). Since SUD was more prevalent in the non-responder
group compared to the responders (with borderline signifi-
cance), we excluded the possibility of bias in the estimation of
the association between the VNTR in SLC6A3 and response to
MPH by including SUD as a covariate, although we did not





number of alleles (%)
Responders number
of alleles (%) OR (95% CI)
SLC6A3 (DAT1)
(VNTR)
10 59 (70.2) 39 (66.1) 20 (33.9) 1 (—)
9, 11 25 (29.8) 13 (52.0) 12 (48.0) 1.8 (0.6–5.2)






10/10 18 (42.9) 14 (77.8) 4 (22.2) 1 (—)
10/11, 10/9 23 (54.8) 11 (47.8) 12 (52.2) 3.8 (1.0–15.2)
9/9 1 (2.4) 1 (100.0) 0 (0.0) (—) Observation
deleted
Allelotype Number of alleles(%) Number of alleles
(%)
Number of alleles (%)
DRD4 ins/del L 63 (75.0) 38 (60.3) 25 (39.7) 1 (—)
S 21 (25.0) 14 (66.7) 7 (33.3) 0.8 (0.2–2.4)






L/L 24 (57.1) 14 (58.3) 10 (41.7) 1 (—)
L/S 15 (35.7) 10 (66.7) 5 (33.3) 0.7 (0.2–2.7)
S/S 3 (7.1) 2 (66.7) 1 (33.3) 0.7 (0.1–8.8)




Number of alleles (%)
DRD4 VNTR Alleles other
than 7 or 2
57 (67.9) 36 (63.2) 21 (36.8) 1 (—)
7, 2 27 (32.1) 16 (59.3) 11 (40.7) 1.2 (0.4–3.3)




Number of alleles (%)
SLC6A2 (NET) ins/
del
2 63 (75.0) 37 (58.7) 26 (41.3) 1 (—)
1 21 (25.0) 15 (71.4) 6 (28.6) 0.6 (0.2–1.8)






2/2 24 (57.1) 13 (54.2) 11 (45.8) 1 (—)
1/2 15 (35.7) 11 (73.3) 4 (26.7) 0.4 (0.1–1.7)
1/1 3 (7.1) 2 (66.7) 1 (33.3) 0.6 (0.0–7.4)
TABLE III. Treatment Response and SLC6A3 (DAT1) Genotype Using Two Rating Scales
Outcome measure Allele/genotype Non-responders N (%) Responders N (%) OR (95% CI)
ADHD-RS 10 37 (62.7) 22 (37.3) 1 (—)
9, 11 11 (44.0) 14 (66.0) 2.1 (0.7–6.2)
10/10 14 (77.8) 4 (22.2) 1 (—)
10/11, 10/9 9 (39.1) 14 (60.9) 5.4 (1.4–21.9)
9/9 1 (100.0) 0 (0.0) (—) Observation
deleted
CGI-S 10 30 (50.8) 29 (49.2) 1 (—)
9, 11 12 (48.0) 13 (52.0) 1.1 (0.4–3.2)
10/10 10 (55.6) 8 (44.4) 1 (—)
10/11, 10/9 10 (40.0) 13 (60.0) 1.6 (0.5–5.6)
9/9 1 (100.0) 0 (0.0) (—) Observation
deleted
ADHD-RS: DSM-IV ADHD rating scale; CGI-S: Clinical Global Impression, Severity scale.
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observe an association between the polymorphisms and the
presence of SUD. The odds ratio for clinical response to MPH
was slightly elevated to 4.6 (95% CI 1.0–20.6), and the odds
ratio’s for response to MPH using the ADHD-RS and CGI-S
changed to 6.4 (95% CI 1.5–31.3) and 1.7 (95% CI 0.5–6.4),
respectively.
In line with our findings from the stratified analysis, the
random effects logistic regression model showed an increased
likelihood of a response to MPH treatment in the heterozygotes
compared with the 10/10 homozygotes (data not shown).
However, the interaction term was not statistically significant
(P¼ 0.101).
DISCUSSION
This is one of the first pharmacogenetic studies of MPH in
adults with ADHD. In spite of adequate dosing of immediate
release MPH up to 0.94 mg/kg/day, the response rate to MPH
observed was lower than the 78% response rate observed in
the most comparable US study using the same design, dosage
per day, and outcome measures [Spencer et al., 1995].
Explanations for this difference may be the use of only
investigator-based outcome measures by Spencer and cow-
orkers, whereas we used both investigator-based and subject-
based ratings (CGI-severity and DSM-IV ADHD rating scale),
although this can only partly explain the difference. A possible
other explanation may be that, although we used the same
dosage per day (1 mg/kg), we used a four to five times a day
dosing regimen, whereas Spencer dosed three times a day,
leading to a lower dose per unit time in our study. We further
enrolled a larger percentage of patients (41% vs. 29%) with
additional psychiatric problems and more impairment on
various measures (lifetime comorbidity, personality disorders,
prior treatment, IQ, school failure, SES). These patients might
show lower response rates than a higher educated population
being referred for underachievement that was included in the
study by Spencer.
The results of our explorative study suggest that the VNTR
in the 30 UTR of the SLC6A3 gene might be associated with the
MPH treatment response. The 10/10 genotype was associated
with a lower probability of a significant reduction in ADHD
symptoms after 3 weeks of treatment, when compared with
genotypes with only a single 10-repeat allele in the stratified
analysis as well as in the random effects logistic regression
model. In the latter analysis the finding did not reach
statistical significance but due to our small sample size and
the relative modest interaction effect, this was not surprising.
Genetic variants in DRD4 and SLC6A2 did not seem to affect
the response to MPH treatment in our patients.
Our findings regarding SLC6A3 support those of earlier
studies by Winsberg and Comings [1999]; Roman et al. [2002];
Cheon et al. [2005]; Gilbert et al. [2006], but are in contrast to
the results published by Kirley et al. [2003]; Stein et al. [2005];
van der Meulen et al. [2005]; McGough et al. [2006]; Mick et al.
[2006]; Zeni et al. [2007]. Although the reason for this
discrepancy is not entirely clear (though several of the points
mentioned in the introduction might apply), several recent
studies have found that the 10-repeat allele is associated with a
higher expression and/or activity of the dopamine transporter,
both in vitro and in vivo [Heinz et al., 2000], though this is
not consistently reported [Krause et al., 2006]. Since ther-
apeutic doses of MPH need to block more than 50% of the
dopamine transporters in order to significantly enhance the
extracellular dopamine concentration [Fuke et al., 2001; Mill
et al., 2002; Volkow et al., 2002; Cheon et al., 2005], the
increased availability of the transporter molecule in the brain
of individuals with the SLC6A3 10/10 genotype could mean
that higher doses of MPH are needed to achieve appropriate
blockade of the dopamine transporter. This is also suggested
by Cheon et al. [2005] who found higher DAT binding ratios
during [123I]IPT SPECT in 10/10 homozygous children com-
pared to other genotypes and also a better response to MPH in
the latter group. Thus, if the dose of MPH is not sufficient in
patients with the 10/10 genotype, which might be the case with
fixed dosing schedules or if low doses are used because of
adverse effects, patients will have a poorer response to
treatment than patients with other genotypes. Conversely, if
dose requirements for the 10/10 homozygotes are met, the
potentially negative effect of the genotype on the clinical
response would be averted and 10/10 genotype carriers may
even have a more pronounced response to MPH treatment,
compared to other genotypes. Although this hypothesis is
purely speculative, findings of a recent study by Lott et al.
[2005] regarding the effects of the SLC6A3 30 VNTR genotype
on the response to amphetamine in adult healthy volunteers
might add some evidence, since the authors indeed observed
non-response in individuals homozygous for the 9/9 genotype
(n¼ 8), an effect that might be masked by the 10/10 effect if
dosing is inadequate. Different durations of treatment may
also (in combination with MPH dose) underlie the contra-
dictory results of SLC6A3 pharmacogenetic studies, with one
or the other allele becoming more important upon long term
treatment than in short term treatment. This fits well with
suggestions of a role of MPH in downregulating DAT
expression [e.g., Cheon et al., 2005]. Interestingly, we found
the association of the 10/10 genotype with the response to MPH
to be most pronounced when this response was measured by
patient self-report rather than with a clinician-completed
scale. This aspect of who reports on response measures should
be taken into account when comparing research data in the
future.
We recognize that the power of our study was limited and
that the results should be considered preliminary, until
replicated. The small sample size may have led to spurious
positive findings (type I error) and may have limited the power
to detect differences between groups that are only moderate in
size. We did not adjust the P-value to the number of tests due to
power considerations because this could increase the type II
error rate too much for this explorative study. The small
sample size might explain why we were not able to confirm the
earlier findings of an association between DRD4 and SLC6A2
and the clinical response to MPH treatment in ADHD in
children. However, this study and others suggest that the
SLC6A3 genotype may be associated with the response to MPH
in children and adults with ADHD. Future studies are needed
to disentangle the differential effects of comorbidity, dosing
regimens and duration of treatment on the moderating effects
of genotypes on treatment response. Furthermore, future
studies should take a more complete look at the candidate
genes by taking additional polymorphisms into account and
assessing LD structure of a gene. From recent studies we
already know that for example other polymorphisms in
SLC6A3 also show association with ADHD [Brookes et al.,
2006; Asherson et al., 2007]. These might be good candidates to
test for association with MPH response, as well.
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